Immunoprecise Financial Statements From 2010 to 2025
| IPA Stock | USD 0.35 0.02 6.06% |
Check Immunoprecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunoprecise Antibodies' main balance sheet or income statement drivers, such as , as well as many indicators such as . Immunoprecise financial statements analysis is a perfect complement when working with Immunoprecise Antibodies Valuation or Volatility modules.
Immunoprecise |
Immunoprecise Antibodies Company Profit Margin Analysis
Immunoprecise Antibodies' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Immunoprecise Antibodies Profit Margin | (1.16) % |
Most of Immunoprecise Antibodies' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunoprecise Antibodies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Immunoprecise Antibodies has a Profit Margin of -1.1593%. This is 89.66% lower than that of the Biotechnology sector and 94.97% lower than that of the Health Care industry. The profit margin for all United States stocks is 8.72% lower than that of the firm.
Immunoprecise Antibodies Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immunoprecise Antibodies's current stock value. Our valuation model uses many indicators to compare Immunoprecise Antibodies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immunoprecise Antibodies competition to find correlations between indicators driving Immunoprecise Antibodies's intrinsic value. More Info.Immunoprecise Antibodies is rated below average in return on equity category among its peers. It is rated second overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunoprecise Antibodies' earnings, one of the primary drivers of an investment's value.About Immunoprecise Antibodies Financial Statements
Immunoprecise Antibodies stakeholders use historical fundamental indicators, such as Immunoprecise Antibodies' revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunoprecise Antibodies investors may analyze each financial statement separately, they are all interrelated. For example, changes in Immunoprecise Antibodies' assets and liabilities are reflected in the revenues and expenses on Immunoprecise Antibodies' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Immunoprecise Antibodies. Please read more on our technical analysis and fundamental analysis pages.
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies is traded on NASDAQ Exchange in the United States.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:Check out the analysis of Immunoprecise Antibodies Correlation against competitors. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.